Corona Remedies is scheduled to make its stock market debut on Monday, December 15, 2025, with grey market trends pointing to a strong listing. The IPO attracted robust investor interest during its three-day subscription window, closing with an overall subscription of 137.04 times the shares available.
Based in Gujarat, the pharmaceutical company focuses on developing and manufacturing products across key therapeutic segments such as women’s healthcare and cardio-diabetes. Ahead of the listing, market sentiment remains upbeat. As of Sunday, December 14, the grey market premium for the Corona Remedies IPO stood at ₹295 per share. With the upper issue price fixed at ₹1,062, the stock is expected to list near ₹1,357, implying a potential gain of around 28 percent. The GMP reflects investor demand for shares ahead of the official listing.
Shivani Nyati, Head of Wealth at Swastika Investmart, expects a healthy debut, estimating a listing premium of 25–27 percent, with prices likely in the ₹1,330–₹1,350 range.
Subscription data from the BSE highlights heavy participation across all categories. Qualified Institutional Buyers led the demand, subscribing 278.52 times, followed by Non-Institutional Investors at 208.88 times. Retail investors also showed strong interest, subscribing 28.73 times their allotted portion.